Comparator Drugs: Meeting Speed-To-Market Demands

Comparator drugs and clinical trial supplies are critical to all trials, particularly in phase III.

This phase examines the efficacy, as well as the safety, of the new drug and usually involves 1,000 to 3,000 patients in clinics and hospitals.¹⁴ The outcome/biostatistical data of phase III trials is submitted to the FDA in order to obtain approval of a new drug.